HC Wainwright Has Negative Outlook of Kamada FY2024 Earnings

Kamada Ltd. (NASDAQ:KMDA) – Investment analysts at HC Wainwright cut their FY2024 earnings per share (EPS) estimates for shares of Kamada in a research note issued on Thursday, November 14th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will earn $0.25 per share for the year, down from their prior forecast of $0.28. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Kamada’s current full-year earnings is $0.24 per share.

Separately, StockNews.com cut shares of Kamada from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 27th.

Kamada Stock Performance

Shares of NASDAQ:KMDA opened at $5.95 on Monday. The company has a market capitalization of $342.01 million, a P/E ratio of 21.25 and a beta of 1.05. The company’s 50-day moving average is $5.49 and its 200 day moving average is $5.47. Kamada has a fifty-two week low of $4.60 and a fifty-two week high of $6.53.

Institutional Trading of Kamada

Hedge funds have recently made changes to their positions in the company. Public Employees Retirement System of Ohio bought a new position in shares of Kamada during the 3rd quarter worth $77,000. Plato Investment Management Ltd bought a new position in Kamada during the third quarter worth about $117,000. Vanguard Group Inc. boosted its position in Kamada by 8.2% during the first quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock worth $7,433,000 after purchasing an additional 100,800 shares during the period. Finally, Y.D. More Investments Ltd increased its stake in shares of Kamada by 1,956.0% in the second quarter. Y.D. More Investments Ltd now owns 726,161 shares of the biotechnology company’s stock worth $3,643,000 after purchasing an additional 690,842 shares in the last quarter. 20.38% of the stock is currently owned by institutional investors.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.